This is barberry root — Berberis vulgaris. This is goldenseal — Hydrastis canadensis. Both contain berberine, a naturally occurring alkaloid that has been used in herbal medicine across multiple traditions for thousands of years. Berberine is now one of the most widely researched botanical compounds in the world, with clinical trials showing efficacy in blood sugar regulation, lipid management, and gut health.
In January 2026, the European Food Safety Authority released a 195-page draft opinion that concluded: it was not possible to establish a safe level of intake for berberine.
That sentence needs unpacking carefully — because it does not mean what most people reading it will assume it means.
**The concern **
EFSA's concern rests on three pillars: in vitro genotoxicity signals, drug interactions via CYP2D6 and CYP3A4 inhibition, and cardiac safety signals including QT interval prolongation.
In vitro genotoxicity: berberine does show positive signals in some cell-culture genotoxicity assays. I will not dismiss this. The question is what it means at human supplement doses in vivo — in actual living bodies. And on that question, the evidence is genuinely limited. The NTP animal carcinogenicity bioassays for berberine are not complete. EFSA's "cannot establish safe intake" conclusion is partly driven by this data gap — the absence of definitive in vivo safety data — rather than by demonstrated in vivo genotoxic harm. The CEHTRA analysis published alongside the EFSA opinion makes this explicit. Data insufficiency was treated as a risk signal. That is a precautionary posture, and it is not the same as a demonstrated toxicological finding.
CYP2D6 and CYP3A4 inhibition: this is real and clinically important. Unlike St John's Wort, which induces these enzymes and reduces drug levels, berberine inhibits them, which increases plasma levels of co-administered drugs that are metabolised by these pathways. This matters clinically for many antidepressants metabolised by CYP2D6 and for a broad range of drugs metabolised by CYP3A4. At supplement doses of 500 to 1,500 milligrams per day, the magnitude of this inhibition compared to established pharmaceutical CYP inhibitors has not been fully quantified — but the direction of the effect is well-characterised and the prescriber should be aware of it.
QT prolongation: a case report of torsades de pointes — a potentially life-threatening cardiac arrhythmia — associated with berberine supplementation was published in Cureus in 2025. I am citing this honestly. It is a real cardiac safety signal. The dose-dependency of the QT effect is supported by animal and pharmacological data, and randomised controlled trial data at 600 to 1,000 milligrams per day found a good safety profile and that the supplement was well tolerated. But patients with long QT syndrome, pre-existing cardiac arrhythmia, or concurrent QT-prolonging medications are a population where berberine requires real caution. Berberine should not be prescribed to those patients without specialist oversight.
The whole plant versus isolated alkaloid distinction.
Berberine-containing plants — barberry, goldenseal, huang lian — have been used in Traditional Chinese Medicine, Ayurveda, and North American indigenous medicine for thousands of years. The adverse event profile of modern high-dose isolated berberine alkaloid at 1,500 milligrams per day is not the same pharmacological entity as a traditional barberry tincture or a goldenseal decoction.
Traditional preparations deliver berberine at lower concentrations, alongside dozens of other phytochemicals that may modulate its absorption and activity. The EFSA assessment is driven primarily by data on isolated berberine alkaloid — which is the product sold in many modern supplements. A proportionate regulatory response would distinguish between traditional whole-plant preparations and high-dose isolated alkaloid products. A blanket restriction on every plant species containing berberine eliminates thousands of years of traditional use along with the modern isolated-alkaloid supplement.
Hypoglycaemia and pregnancy — genuine clinical precautions.
Berberine has documented hypoglycaemic effects. In patients taking pharmaceutical antidiabetic agents, combination with berberine may potentiate the glucose-lowering effect. This is a real clinical interaction requiring monitoring. It is not a reason for prohibition — it is a reason for prescriber awareness.
Berberine has known uterotonic effects documented in animal studies, and pregnancy avoidance is appropriate clinical guidance. This is established clinical practice in herbal medicine. It is not the same as prohibiting access for the general adult population.
The constitutional close.
EFSA's "cannot establish safe intake" conclusion for berberine is a precautionary statement made in the face of data gaps — not a conclusion that harm has been demonstrated. Meanwhile, goldenseal and barberry have millennia of traditional use without the epidemic of adverse events this regulatory language implies.
The UK Government committed to align food supplement law with EU law under the SPS Agreement — without parliamentary approval. Published at www.gov.uk/government/news/uk-eu-sps-agreement-legislation-in-scope .
Sign the petition. Respond to the consultation. Write to your MP at writetothem.com. Parliament should decide — not Brussels. https://www.change.org/p/demand-uk-regain-control-over-food-supplements-regulation?recruiter=1403120945&recruited_by_id=ca366360-0a66-11f1-a119-071922cd5010&share_id=Qv72WrhZDN #RightToHeal #HerbalAccessNI #SaveOurSupplements
